Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q35621693)
Watch
English
Entecavir, FTC, L-FMAU, LdT and others
scientific article published on January 2003
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PubMed ID
14708692
retrieved
9 August 2017
review article
1 reference
stated in
Europe PubMed Central
title
Entecavir, FTC, L-FMAU, LdT and others
(English)
1 reference
stated in
Europe PubMed Central
PubMed ID
14708692
retrieved
9 August 2017
main subject
entecavir
1 reference
based on heuristic
inferred from title
author
Maria Buti
series ordinal
1
object named as
Maria Buti
1 reference
stated in
Europe PubMed Central
PubMed ID
14708692
retrieved
9 August 2017
author name string
Rafael Esteban
series ordinal
2
1 reference
stated in
Europe PubMed Central
PubMed ID
14708692
retrieved
9 August 2017
publication date
1 January 2003
1 reference
stated in
Europe PubMed Central
PubMed ID
14708692
retrieved
9 August 2017
published in
Journal of Hepatology
1 reference
stated in
Europe PubMed Central
PubMed ID
14708692
retrieved
9 August 2017
volume
39 Suppl 1
1 reference
stated in
Europe PubMed Central
PubMed ID
14708692
retrieved
9 August 2017
page(s)
S139-42
1 reference
stated in
Europe PubMed Central
PubMed ID
14708692
retrieved
9 August 2017
cites work
Management of hepatitis B: 2000--summary of a workshop
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900316-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Antiviral drugs.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900316-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Metabolic studies on BMS-200475, a new antiviral compound active against hepatitis B virus
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900316-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Potent efficacy of entecavir (BMS-200475) in a duck model of hepatitis B virus replication
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900316-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900316-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900316-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900316-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Dynamics of hepatitis B virus infection in vivo
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900316-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Hepatitis B virus immunopathogenesis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900316-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Viral dynamics during and after entecavir therapy in patients with chronic hepatitis B.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900316-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Antiviral activity of clevudine [L-FMAU, (1-(2-fluoro-5-methyl-beta, L-arabinofuranosyl) uracil)] against woodchuck hepatitis virus replication and gene expression in chronically infected woodchucks (Marmota monax).
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900316-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Characterization of the antiviral effect of 2',3'-dideoxy-2', 3'-didehydro-beta-L-5-fluorocytidine in the duck hepatitis B virus infection model.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900316-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Inhibition of hepatitis B virus by a novel L-nucleoside, 2'-fluoro-5-methyl-beta-L-arabinofuranosyl uracil
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900316-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Synthesis and antiviral evaluation of some beta-L-2', 3'-dideoxy-5-chloropyrimidine nucleosides and pronucleotides
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900316-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Identifiers
DOI
10.1016/S0168-8278(03)00316-7
1 reference
stated in
Europe PubMed Central
PubMed ID
14708692
retrieved
9 August 2017
PubMed ID
14708692
1 reference
stated in
Europe PubMed Central
PubMed ID
14708692
retrieved
9 August 2017
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
